Information on this site is not intended as medical advice and should not be used as a substitute for consulting with a qualified doctor.
The active substance in Tarceva, erlotinib, is a cancer medicine that belongs to the group (Epidermal Growth Factor Receptor) ‘EGFR inhibitors’. Erlotinib blocks EGFRs, which can be found on the surface of some tumour cells. As a result of this block, the tumour cells can no longer receive the messages needed for growth, progression and spreading (metastasis). As a result, Tarceva helps to stop the cancer from growing, multiplying and spreading through the body.1
In Bangladesh Tarceva is approved for the following indications.2
Non-small cell lung cancer:
- Tarceva is indicated for the first-line and maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations.
- Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Pancreatic cancer:
- Tarceva in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
For more disease and medicine related queries you may discuss with your physician.
In Bangladesh Tarceva is available as
100 mg tablets
150 mg tablets
To ensure patient safety and quality, it is strongly recommended to verify that, each medicine comes with the Roche Hologram Sticker, DGDA approved DAR (Drug Administration Registration) Number imprinted on it. Neither Radiant nor Roche Bangladesh takes liability of any other sources of products.
References
Tarceva | European Medicines Agency. How does Tarceva work? [Internet; cited 2018, December 03]. Retrieved from
Tarceva Product Information _ FE-English Ro 50-8231 _ September 2021
This website contains information which is targeted to the people of Bangladesh and could contain product details or information otherwise not accessible or valid in your country. Roche Bangladesh is not responsible for accessing such information that may not be in accordance with legal, regulatory, registration or use processes in your home country. Please note that, information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor. We are unable to answer questions on individual disease treatment/ management matters. These should be discussed with your physician. We cannot answer product-related questions through this website. Nor this site acts as promotional/ commercial tool for products. It is not permissible to take the contents of this site and use it for commercial purpose, without written consent of Roche Bangladesh.